<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>SEPTOCAINE AND EPINEPHRINE- articaine hydrochloride and epinephrine bitartrate injection, solution </strong><br>Septodont Inc.<br></p></div>
<div id="Highlights" class="Highlights"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1>HIGHLIGHTS OF PRESCRIBING INFORMATION</h1>
<div class="HighlightsDisclaimer">These highlights do not include all the information needed to use Septocaine® safely and effectively. See full prescribing information for Septocaine®. <br>Septocaine® (articaine HCl and epinephrine) Injection; Intraoral Submucosal Injection<br> <br>Articaine hydrochloride 4% and epinephrine 1:200,000<br>Articaine hydrochloride 4% and epinephrine 1:100,000  <br> <br>Initial U.S. Approval: 2000</div>
<div></div>
<div class="HighlightSection">
<h1 class="Highlights"><span>INDICATIONS AND USAGE</span></h1>
<div><p class="Highlighta">Septocaine®, an amide local anesthetic containing a vasoconstrictor, is indicated for local, infiltrative, or conductive anesthesia in both simple and complex dental procedures.  (<a href="#section-1">1</a>)</p></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE AND ADMINISTRATION</span></h1>
<div>
<p class="Highlighta">For dental injection by submucosal infiltration or nerve block. (<a href="#S2.1">2.1</a>) </p>
<ul>
<li> For infiltration:  0.5-2.5 mL (20-100 mg articaine HCl) (<a href="#S2.1">2.1</a>)</li>
<li> For nerve block:  0.5-3.4 mL (20-136 mg articaine HCl) (<a href="#S2.1">2.1</a>)</li>
<li> For oral surgery:  1.0-5.1 mL (40-204 mg articaine HCl) (<a href="#S2.1">2.1</a>)</li>
<li> For most routine dental procedures, Septocaine® containing epinephrine 1:200,000 is preferred. However, when more pronounced hemostasis or improved visualization of the surgical field are required, Septocaine® containing epinephrine 1:100,000 may be used. (<a href="#S2.1">2.1</a>)</li>
<li> Dosages should be reduced in pediatric patients, elderly patients, and patients with cardiac or liver disease. (<a href="#S2.1">2.1</a>)</li>
</ul>
<p class="Highlighta">Maximum recommended dosages (<a href="#S2.2">2.2</a>): </p>
<ul>
<li> Adults: 7 mg/kg (0.175 mL/kg)</li>
<li> Children 4-16 years: 7 mg/kg (0.175 mL/kg), depending on the age, weight and magnitude of the operation.</li>
</ul>
</div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE FORMS AND STRENGTHS</span></h1>
<div>
<p class="Highlighta">Injection (clear colorless solution), containing: </p>
<ul>
<li> Articaine hydrochloride 4% (40 mg/mL) and epinephrine 1:200,000 (as epinephrine bitartrate 0.009 mg/mL) (<a href="#S3">3</a>)</li>
<li> Articaine hydrochloride 4% (40 mg/mL) and epinephrine 1:100,000 (as epinephrine bitartrate 0.018 mg/mL) (<a href="#S3">3</a>)</li>
</ul>
</div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>CONTRAINDICATIONS</span></h1>
<div><p class="Highlighta"><span class="Bold"> Known <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to sulfite. (<a href="#S4">4</a>)</span> </p></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>WARNINGS AND PRECAUTIONS</span></h1>
<div><ul>
<li>
<span class="Bold">Accidental Intravascular Injection: </span> May be associated with <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsions</span> followed by <span class="product-label-link" type="condition" conceptid="380834" conceptname="Coma">coma</span> and <span class="product-label-link" type="condition" conceptid="317109" conceptname="Respiratory arrest">respiratory arrest</span>. Resuscitative equipment, oxygen and other resuscitative drugs should be available. (<a href="#S5.1">5.1</a>)</li>
<li>
<span class="Bold">Systemic Toxicity</span> (<a href="#S5.2">5.2</a>)</li>
<li>
<span class="Bold">Vasoconstrictor Toxicity:</span> Local anesthetic solutions like Septocaine® that contain a vasoconstrictor should be used cautiously, especially in patients with impaired cardiovascular function or vascular disease. (<a href="#S5.3">5.3</a>)</li>
<li>
<span class="Bold"><span class="product-label-link" type="condition" conceptid="432882" conceptname="Methemoglobinemia">Methemoglobinemia</span> </span>(<a href="#S5.4">5.4</a>)</li>
<li>
<span class="Bold"><span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">Anaphylaxis</span> and Allergic-Type Reactions</span> (<a href="#S5.5">5.5</a>)</li>
</ul></div>
<div></div>
<div></div>
<div></div>
<div><div></div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>ADVERSE REACTIONS</span></h1>
<div>
<p class="Highlighta">The most common adverse reactions (incidence &gt;2%) are <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span> and <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>. (<a href="#S6.1">6.1</a>) </p>
<br><p class="Highlighta"><span class="Bold">To report SUSPECTED ADVERSE REACTIONS, contact Septodont at 1-800-872-8305 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.</span> </p>
</div>
<div>
<div></div>
<div></div>
</div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DRUG INTERACTIONS</span></h1>
<div><ul>
<li> Monoamine oxidase inhibitors, nonselective beta adrenergic antagonists, or tricyclic antidepressants may produce severe, prolonged <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span> (<a href="#S7">7</a>)</li>
<li> Phenothiazines and butyrophenones may reduce or reverse the pressor effect of epinephrine (<a href="#S7">7</a>)</li>
</ul></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>USE IN SPECIFIC POPULATIONS</span></h1>
<div><ul>
<li>
<span class="Bold">Pregnancy:</span> Based on animal studies, may cause fetal harm. (<a href="#S8.1">8.1</a>)</li>
<li>
<span class="Bold">Nursing Mothers:</span> Exercise caution when administering to a nursing woman. (<a href="#S8.3">8.3</a>)</li>
<li>
<span class="Bold">Pediatric Use:</span>  Safety and effectiveness in pediatric patients below the age of 4 years have not been established. (<a href="#S8.4">8.4</a>)</li>
</ul></div>
<div><div></div></div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div>
<div></div>
<div></div>
<div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
</div>
<div><div></div></div>
<div></div>
<div></div>
<div><div></div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<p class="HighlightsSeeReference">See 17 for PATIENT COUNSELING INFORMATION.</p>
<p class="HighlightsRevision">Revised: 1/2011</p>
</div></td></tr></table></div>
<div id="Index" class="Index"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1 class="Colspan">FULL PRESCRIBING INFORMATION: CONTENTS<a href="#footnote-content" name="footnote-reference-content">*</a>
</h1>
<h1><a href="#section-1" class="toc">1	INDICATIONS AND USAGE</a></h1>
<h1><a href="#section-2" class="toc">2	DOSAGE AND ADMINISTRATION</a></h1>
<h2><a href="#section-2.1" class="toc">2.1	General Dosing Information</a></h2>
<h2><a href="#section-2.2" class="toc">2.2	Maximum Recommended Dosages</a></h2>
<h2><a href="#section-2.3" class="toc">2.3	Dosing in Special Populations</a></h2>
<h1><a href="#section-3" class="toc">3	DOSAGE FORMS AND STRENGTHS</a></h1>
<h1><a href="#section-4" class="toc">4	CONTRAINDICATIONS</a></h1>
<h1><a href="#section-5" class="toc">5	WARNINGS AND PRECAUTIONS</a></h1>
<h2><a href="#section-5.1" class="toc">5.1 	Accidental Intravascular Injection</a></h2>
<h2><a href="#section-5.2" class="toc">5.2    Systemic Toxicity</a></h2>
<h2><a href="#section-5.3" class="toc">5.3 Vasoconstrictor Toxicity</a></h2>
<h2><a href="#section-5.4" class="toc">5.4 <span class="product-label-link" type="condition" conceptid="432882" conceptname="Methemoglobinemia">Methemoglobinemia</span></a></h2>
<h2><a href="#section-5.5" class="toc">5.5 <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">Anaphylaxis</span> and Allergic-Type Reactions</a></h2>
<h1><a href="#section-6" class="toc">6	ADVERSE REACTIONS</a></h1>
<h2><a href="#section-6.1" class="toc">6.1	Clinical Studies Experience</a></h2>
<h2><a href="#section-6.2" class="toc">6.2	Postmarketing Experience</a></h2>
<h1><a href="#section-7" class="toc">7	DRUG INTERACTIONS</a></h1>
<h1><a href="#section-8" class="toc">8	USE IN SPECIFIC POPULATIONS</a></h1>
<h2><a href="#section-8.1" class="toc">8.1	Pregnancy</a></h2>
<h2><a href="#section-8.2" class="toc">8.3	Nursing Mothers</a></h2>
<h2><a href="#section-8.3" class="toc">8.4	Pediatric Use</a></h2>
<h2><a href="#section-8.4" class="toc">8.5	Geriatric Use</a></h2>
<h2><a href="#section-8.5" class="toc">8.6	Renal/<span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">Hepatic Insufficiency</span></a></h2>
<h1><a href="#section-9" class="toc">10	OVERDOSAGE</a></h1>
<h1><a href="#section-10" class="toc">11	DESCRIPTION</a></h1>
<h1><a href="#section-11" class="toc">12   CLINICAL PHARMACOLOGY</a></h1>
<h2><a href="#section-11.1" class="toc">12.1	Mechanism of Action</a></h2>
<h2><a href="#section-11.2" class="toc">12.2	Pharmacodynamics</a></h2>
<h2><a href="#section-11.3" class="toc">12.3	Pharmacokinetics</a></h2>
<h1><a href="#section-12" class="toc">13   NONCLINICAL TOXICOLOGY</a></h1>
<h2><a href="#section-12.1" class="toc">13.1	Carcinogenesis, Mutagenesis, Impairment of Fertility</a></h2>
<h1><a href="#section-13" class="toc">14   CLINICAL STUDIES</a></h1>
<h1><a href="#section-14" class="toc">15	REFERENCES</a></h1>
<h1><a href="#section-15" class="toc">16	HOW SUPPLIED/STORAGE AND HANDLING</a></h1>
<h1><a href="#section-16" class="toc">17	PATIENT COUNSELING INFORMATION</a></h1>
<dl class="Footnote">
<dt><a href="#footnote-reference-content" name="footnote-content">*</a></dt>
<dd>Sections or subsections omitted from the full prescribing information are not listed.</dd>
</dl>
</div></td></tr></table></div>
<div class="Contents">
<h1>FULL PRESCRIBING INFORMATION</h1>
<div class="Section" data-sectionCode="48780-1">
<a name="DLDE"></a><a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="S1"></a><a name="section-1"></a><p></p>
<h1>1	INDICATIONS AND USAGE</h1>
<p class="First">Septocaine®, an amide local anesthetic containing a vasoconstrictor, is indicated for local, infiltrative, or conductive anesthesia in both simple and complex dental procedures.</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="S2"></a><a name="section-2"></a><p></p>
<h1>2	DOSAGE AND ADMINISTRATION</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="S2.1"></a><a name="section-2.1"></a><p></p>
<h2>2.1	General Dosing Information</h2>
<p class="First">Table 1 (below) summarizes the recommended volumes and concentrations of Septocaine® for various types of anesthetic procedures. The dosages suggested in this table are for normal healthy adults, administered by submucosal infiltration or nerve block.</p>
<a name="table1"></a><table width="75%">
<caption><span>Table 1: Recommended Dosages for Both Strengths</span></caption>
<col align="left" valign="middle" width="30%">
<col align="left" valign="middle" width="30%">
<col align="left" valign="middle" width="40%">
<thead>
<tr class="Botrule First">
<th class="Lrule Rrule" align="left" rowspan="2">Procedure</th>
<th class="Rrule" align="left" colspan="2" valign="bottom">Septocaine® Injection</th>
</tr>
<tr class="Last">
<th class="Rrule" align="left" valign="top">Volume (mL)</th>
<th class="Rrule" align="left" valign="top">Total dose of articaine HCl (mg)</th>
</tr>
</thead>
<tbody>
<tr class="Botrule First">
<td class="Lrule Rrule" align="left">Infiltration</td>
<td class="Rrule" align="left">0.5 – 2.5</td>
<td class="Rrule" align="left">20 – 100</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Nerve block</td>
<td class="Rrule" align="left">0.5 – 3.4</td>
<td class="Rrule" align="left">20 – 136</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" align="left">Oral surgery</td>
<td class="Rrule" align="left">1.0 – 5.1</td>
<td class="Rrule" align="left">40 – 204</td>
</tr>
</tbody>
</table>
<p>The recommended doses serve only as a guide to the amount of anesthetic required for most routine procedures. The actual volumes to be used depend on a number of factors such as type and extent of surgical procedure, depth of anesthesia, degree of muscular relaxation, and condition of the patient. In all cases, the smallest dose that will produce the desired result should be given.</p>
<p>The onset of anesthesia and the duration of anesthesia are proportional to the volume and concentration (i.e., total dose) of local anesthetic used. Caution should be exercised when employing large volumes because the incidence of side effects may be dose-related.</p>
<p>For most routine dental procedures, Septocaine® containing epinephrine 1:200,000 is preferred. However, when more pronounced hemostasis or improved visualization of the surgical field are required, Septocaine® containing epinephrine 1:100,000 may be used.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S2.2"></a><a name="section-2.2"></a><p></p>
<h2>2.2	Maximum Recommended Dosages</h2>
<ul>
<li>
<span class="Bold">Adults:</span> For normal healthy adults, the maximum dose of articaine HCl administered by submucosal infiltration or nerve block should not exceed 7 mg/kg (0.175 mL/kg).</li>
<li>
<span class="Bold">Pediatric Patients Ages 4 to 16 Years:</span> The quantity of articaine HCl in children ages 4 to 16 years of age to be injected should be determined by the age and weight of the child and the magnitude of the operation. The maximum dose of articaine HCl 4% should not exceed 7 mg/kg (0.175 mL/kg) <span class="Italics">[see <a href="#S8.4">Use in Specific Populations (8.4)</a>].</span>
</li>
<li> Safety and effectiveness of Septocaine® in pediatric patients below the age of 4 years have not been established.</li>
</ul>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S2.3"></a><a name="section-2.3"></a><p></p>
<h2>2.3	Dosing in Special Populations</h2>
<p class="First">Dose reduction may be required in debilitated patients, acutely ill patients, elderly patients, and pediatric patients commensurate with their age and physical condition. No studies have been performed in patients with renal or liver dysfunction. Caution should be used in patients with severe liver disease. [<span class="Italics">see <a href="#S5.2">Warnings and Precautions (5.2)</a>, <a href="#S8.4">Use in Specific Populations (8.4</a>, <a href="#S8.5">8.5</a>, and <a href="#S8.6">8.6)</a>]</span></p>
</div>
</div>
<div class="Section" data-sectionCode="43678-2">
<a name="S3"></a><a name="section-3"></a><p></p>
<h1>3	DOSAGE FORMS AND STRENGTHS</h1>
<p class="First">Injection (clear colorless solution), containing:</p>
<ul>
<li> Articaine hydrochloride 4% (40 mg/mL) and epinephrine 1:200,000 (as epinephrine bitartrate 0.009 mg/mL)</li>
<li> Articaine hydrochloride 4% (40 mg/mL) and epinephrine 1:100,000 (as epinephrine bitartrate 0.018 mg/mL)</li>
</ul>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="S4"></a><a name="section-4"></a><p></p>
<h1>4	CONTRAINDICATIONS</h1>
<p class="First">Septocaine is contraindicated in patients who are hypersensitive to products containing sulfites. Products containing sulfites may cause allergic-type reactions including anaphylactic symptoms and life-threatening or less severe <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthmatic</span> episodes in certain susceptible people. Sulfite sensitivity is seen more frequently in <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthmatic</span> than in non-<span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthmatic</span> people <span class="Italics">[see <a href="#S5.5">Warnings and Precautions (5.5)</a>].</span></p>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="S5"></a><a name="section-5"></a><p></p>
<h1>5	WARNINGS AND PRECAUTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.1"></a><a name="section-5.1"></a><p></p>
<h2>5.1 	Accidental Intravascular Injection</h2>
<p class="First">  Accidental intravascular injection of Septocaine® may be associated with <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsions</span>, followed by central nervous system or cardiorespiratory <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> and <span class="product-label-link" type="condition" conceptid="380834" conceptname="Coma">coma</span>, progressing ultimately to <span class="product-label-link" type="condition" conceptid="317109" conceptname="Respiratory arrest">respiratory arrest</span>. Dental practitioners who employ local anesthetic agents including Septocaine® should be well versed in diagnosis and management of emergencies that may arise from their use. Resuscitative equipment, oxygen, and other resuscitative drugs should be available for immediate use. To avoid intravascular injection, <span class="product-label-link" type="condition" conceptid="4239038" conceptname="Pulmonary aspiration">aspiration</span> should be performed before Septocaine® is injected. The needle must be repositioned until no return of blood can be elicited by <span class="product-label-link" type="condition" conceptid="4239038" conceptname="Pulmonary aspiration">aspiration</span>. Note, however, that the absence of blood in the syringe does not guarantee that intravascular injection has been avoided.</p>
<p>Small doses of local anesthetics injected in dental blocks may produce adverse reactions similar to systemic toxicity seen with unintentional intravascular injections of larger doses. <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">Confusion</span>, <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsions</span>, <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span> or <span class="product-label-link" type="condition" conceptid="317109" conceptname="Respiratory arrest">respiratory arrest</span>, and cardiovascular stimulation or <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> have been reported. These reactions may be due to intra-arterial injection of the local anesthetic with retrograde flow to the cerebral circulation. Patients receiving these blocks should be observed constantly. Resuscitative equipment and personnel for treating adverse reactions should be immediately available. Dosage recommendations should not be exceeded <span class="Italics">[see <a href="#S2.1">Dosage and Administration (2.1)</a>].</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.2"></a><a name="section-5.2"></a><p></p>
<h2>5.2    Systemic Toxicity</h2>
<p class="First">  This includes toxicity arising from accidental intravascular injection of Septocaine® discussed in Section 5.1, as well as that related to higher systemic concentrations of local anesthetics or epinephrine <span class="Italics">[see <a href="#S5.3">Warnings and Precautions (5.3)</a>].</span> Systemic absorption of local anesthetics including Septocaine® can produce effects on the central nervous and cardiovascular systems.</p>
<p>At blood concentrations achieved with therapeutic doses of Septocaine®, changes in cardiac conduction, <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">excitability</span>, refractoriness, contractility, and peripheral <span class="product-label-link" type="condition" conceptid="4089490" conceptname="Vascular resistance">vascular resistance</span> are minimal. However, toxic blood concentrations of Septocaine® can depress cardiac conduction and <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">excitability</span>, which may lead to <span class="product-label-link" type="condition" conceptid="316135" conceptname="Atrioventricular block">atrioventricular block</span>, <span class="product-label-link" type="condition" conceptid="4185572" conceptname="Ventricular arrhythmia">ventricular arrhythmias</span>, and <span class="product-label-link" type="condition" conceptid="321042" conceptname="Cardiac arrest">cardiac arrest</span>, possibly resulting in fatalities. In addition, myocardial contractility is depressed and <span class="product-label-link" type="condition" conceptid="4237053" conceptname="Vasodilatation">peripheral vasodilatation</span> occurs, leading to decreased <span class="product-label-link" type="condition" conceptid="4221102" conceptname="Cardiac output">cardiac output</span> and arterial blood pressure. Septocaine® should also be used with caution in patients with <span class="product-label-link" type="condition" conceptid="316135" conceptname="Atrioventricular block">heart block</span> as well as those with impaired cardiovascular function since they may be less able to compensate for functional changes associated with the prolongation of A-V conduction produced by these drugs.</p>
<p><span class="product-label-link" type="condition" conceptid="4012381" conceptname="Restlessness">Restlessness</span>, <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">anxiety</span>, <span class="product-label-link" type="condition" conceptid="377575" conceptname="Tinnitus">tinnitus</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="4079185" conceptname="Hazy vision">blurred vision</span>, <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremors</span>, <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>, or <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">drowsiness</span> may be early warning signs of central nervous system toxicity.</p>
<p>Careful and constant monitoring of cardiovascular and respiratory (adequacy of ventilation) vital signs and the patient's state of consciousness should be performed after each local anesthetic injection of Septocaine®. Repeated doses of Septocaine® may cause significant increases in blood levels because of possible accumulation of the drug or its metabolites. The lowest dosage that results in effective anesthesia should be used to decrease the risk of high plasma levels and serious adverse effects. Tolerance to elevated blood levels varies with the status of the patient. Resuscitative equipment, oxygen, and other resuscitative drugs should be available for immediate use. Precautions for epinephrine administration, discussed in Section 5.3, should be observed. </p>
<p>  Debilitated patients, elderly patients, acutely ill patients, and pediatric patients should be given reduced doses commensurate with their age and physical condition <span class="Italics">[see <a href="#S2.1">Dosage and Administration (2.1</a>, <a href="#S2.3">2.3)</a>]. </span>No studies have been performed in patients with liver dysfunction, and caution should be used in patients with severe <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic disease</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.3"></a><a name="section-5.3"></a><p></p>
<h2>5.3 Vasoconstrictor Toxicity</h2>
<p class="First">Septocaine® contains epinephrine, a vasoconstrictor that can cause local or systemic toxicity and should be used cautiously. Local toxicity may include ischemic injury or <span class="product-label-link" type="condition" conceptid="4280654" conceptname="Necrosis">necrosis</span>, which may be related to vascular spasm. Septocaine® should be used with caution in patients during and following the administration of potent general anesthetic agents, since <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">cardiac arrhythmias</span> may occur under such conditions. Patients with <span class="product-label-link" type="condition" conceptid="321052" conceptname="Peripheral vascular disease">peripheral vascular disease</span> and those with hypertensive vascular disease may exhibit exaggerated vasoconstrictor response.</p>
<p>The American Heart Association has made the following recommendation regarding the use of local anesthetics with vasoconstrictors in patients with <span class="product-label-link" type="condition" conceptid="4124683" conceptname="Silent myocardial ischemia">ischemic heart disease</span>: "Vasoconstrictor agents should be used in local anesthesia solutions during dental practice only when it is clear that the procedure will be shortened or the <span class="product-label-link" type="condition" conceptid="4242687" conceptname="No sensitivity to pain">analgesia</span> rendered more profound. When a vasoconstrictor is indicated, extreme care should be taken to avoid intravascular injection. The minimum possible amount of vasoconstrictor should be used." (Kaplan, 1986).</p>
<p>   It is essential to aspirate before any injection to avoid administration of the drug into the blood stream.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.4"></a><a name="section-5.4"></a><p></p>
<h2>5.4 <span class="product-label-link" type="condition" conceptid="432882" conceptname="Methemoglobinemia">Methemoglobinemia</span></h2>
<p class="First">  Articaine, like other local anesthetics, can cause <span class="product-label-link" type="condition" conceptid="432882" conceptname="Methemoglobinemia">methemoglobinemia</span>, particularly in conjunction with methemoglobin-inducing agents. Septocaine® should not be used in patients with congenital or idiopathic <span class="product-label-link" type="condition" conceptid="432882" conceptname="Methemoglobinemia">methemoglobinemia</span>, or in patients who are receiving treatment with methemoglobin-inducing agents since they are more susceptible to drug-induced <span class="product-label-link" type="condition" conceptid="432882" conceptname="Methemoglobinemia">methemoglobinemia</span>.</p>
<p>Signs and symptoms of <span class="product-label-link" type="condition" conceptid="432882" conceptname="Methemoglobinemia">methemoglobinemia</span> may be delayed some hours after exposure. Initial signs and symptoms of <span class="product-label-link" type="condition" conceptid="432882" conceptname="Methemoglobinemia">methemoglobinemia</span> include slate grey <span class="product-label-link" type="condition" conceptid="438555" conceptname="Cyanosis">cyanosis</span> seen in buccal mucous membranes, lips, and nail beds. In severe cases, symptoms may include central <span class="product-label-link" type="condition" conceptid="438555" conceptname="Cyanosis">cyanosis</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="4061577" conceptname="Lethargy">lethargy</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">syncope</span>, <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">dyspnea</span>, <span class="product-label-link" type="condition" conceptid="4171908" conceptname="Semicoma">CNS depression</span>, <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span>, dysrythmia, and <span class="product-label-link" type="condition" conceptid="201965" conceptname="Shock">shock</span>. <span class="product-label-link" type="condition" conceptid="432882" conceptname="Methemoglobinemia">Methemoglobinemia</span> should be considered if central <span class="product-label-link" type="condition" conceptid="438555" conceptname="Cyanosis">cyanosis</span> unresponsive to oxygen therapy occurs, especially if methemoglobin-inducing agents have been used. Calculated oxygen saturation and pulse oximetry are inaccurate in the setting of <span class="product-label-link" type="condition" conceptid="432882" conceptname="Methemoglobinemia">methemoglobinemia</span>. The diagnosis can be confirmed by an elevated methemoglobin level of at least 10% is present. The development of <span class="product-label-link" type="condition" conceptid="432882" conceptname="Methemoglobinemia">methemoglobinemia</span> is dose-related.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-5.4.1"></a><p></p>
<p class="First"><span class="Bold Underline"><span class="Italics">Management of <span class="product-label-link" type="condition" conceptid="432882" conceptname="Methemoglobinemia">methemoglobinemia</span></span>:</span> If <span class="product-label-link" type="condition" conceptid="432882" conceptname="Methemoglobinemia">methemoglobinemia</span> does not respond to administration of oxygen, clinically significant symptoms of <span class="product-label-link" type="condition" conceptid="432882" conceptname="Methemoglobinemia">methemoglobinemia</span> should be treated with administration of a slow intravenous injection (over 5 minutes) of methylene blue at a dosage of 1-2 mg/kg body weight. </p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.5"></a><a name="section-5.5"></a><p></p>
<h2>5.5 <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">Anaphylaxis</span> and Allergic-Type Reactions</h2>
<p class="First">Septocaine® contains sodium metabisulfite, a sulfite that may cause allergic-type reactions including anaphylactic symptoms and life-threatening or less severe <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthmatic</span> episodes in certain susceptible people. The overall prevalence of sulfite sensitivity in the general population is unknown. Sulfite sensitivity is seen more frequently in <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthmatic</span> than in non-<span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthmatic</span> people.</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="S6"></a><a name="section-6"></a><p></p>
<h1>6	ADVERSE REACTIONS</h1>
<p class="First">Reactions to articaine are characteristic of those associated with other amide-type local anesthetics. Adverse reactions to this group of drugs may also result from excessive plasma levels (which may be due to overdosage, unintentional intravascular injection, or slow metabolic degradation), injection technique, volume of injection, or <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> or they may be idiosyncratic.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="S6.1"></a><a name="section-6.1"></a><p></p>
<h2>6.1	Clinical Studies Experience</h2>
<p class="First">Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. </p>
<p>The reported adverse reactions are derived from clinical trials in the United States and the United Kingdom. Table 2 displays the adverse reactions reported in clinical trials where 882 individuals were exposed to Septocaine® containing epinephrine 1:100,000. Table 3 displays the adverse reactions reported in clinical trials where 182 individuals were exposed to Septocaine® containing epinephrine 1:100,000 and 179 individuals were exposed to Septocaine® containing epinephrine 1:200,000.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-6.1.1"></a><p></p>
<p class="First"><span class="Italics">Adverse reactions observed in at least 1% of patients: </span></p>
<a name="table2"></a><table width="75%">
<caption><span>Table 2: Adverse Reactions in Controlled Trials with an Incidence of 1% or Greater in Patients Administered Septocaine® containing Epinephrine 1:100,000</span></caption>
<col align="left" valign="bottom" width="50%">
<col align="left" valign="bottom" width="50%">
<thead><tr class="First Last">
<th class="Lrule Rrule" align="left">Body System/Reaction</th>
<th class="Rrule" align="left">Septocaine® containing epinephrine 1:100,000  (N=882) Incidence</th>
</tr></thead>
<tbody>
<tr class="Botrule First"><td class="Lrule Rrule" align="left" colspan="2"><span class="Italics">Body as a whole</span></td></tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Face <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">Edema</span></td>
<td class="Rrule" align="left">13 (1%)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span></td>
<td class="Rrule" align="left">31 (4%)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infection</span></td>
<td class="Rrule" align="left">10 (1%)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">Pain</span></td>
<td class="Rrule" align="left">114 (13%)</td>
</tr>
<tr class="Botrule"><td class="Lrule Rrule" align="left" colspan="2"><span class="Italics">Digestive system</span></td></tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="4281516" conceptname="Gingivitis">Gingivitis</span></td>
<td class="Rrule" align="left">13 (1%)</td>
</tr>
<tr class="Botrule"><td class="Lrule Rrule" align="left" colspan="2"><span class="Italics">Nervous system</span></td></tr>
<tr class="Last">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">Paresthesia</span></td>
<td class="Rrule" align="left">11 (1%)</td>
</tr>
</tbody>
</table>
<a name="table3"></a><table width="75%">
<caption><span>Table 3: Adverse Reactions in Controlled Trials with an Incidence of 1% or Greater in Patients Administered Septocaine® containing Epinephrine 1:200,000 and Septocaine® containing Epinephrine 1:100,000</span></caption>
<col align="left" valign="top" width="34%">
<col align="left" valign="top" width="33%">
<col align="left" valign="top" width="33%">
<thead><tr class="First Last">
<th class="Lrule Rrule" align="left" valign="middle">Reaction</th>
<th class="Rrule" align="left">Septocaine® with epinephrine 1:200,000 <br>(N=179)<br>Incidence</th>
<th class="Rrule" align="left">Septocaine® with epinephrine 1:100,000 <br>(N=182)<br>Incidence</th>
</tr></thead>
<tbody>
<tr class="Botrule First">
<td class="Lrule Rrule" align="left">Any adverse reaction</td>
<td class="Rrule" align="left">33 (18%)</td>
<td class="Rrule" align="left">35 (19%)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">Pain</span></td>
<td class="Rrule" align="left">11 (6.1%)</td>
<td class="Rrule" align="left">14 (7.6%)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span></td>
<td class="Rrule" align="left">9 (5%)</td>
<td class="Rrule" align="left">6 (3.2%)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Positive blood <span class="product-label-link" type="condition" conceptid="4239038" conceptname="Pulmonary aspiration">aspiration</span> into syringe</td>
<td class="Rrule" align="left">3 (1.6%)</td>
<td class="Rrule" align="left">6 (3.2%)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">Swelling</span></td>
<td class="Rrule" align="left">3 (1.6%)</td>
<td class="Rrule" align="left">5 (2.7%)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="4339090" conceptname="Trismus">Trismus</span></td>
<td class="Rrule" align="left">1 (0.5%)</td>
<td class="Rrule" align="left">3 (1.6%)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">emesis</span></td>
<td class="Rrule" align="left">3 (1.6%)</td>
<td class="Rrule" align="left">0 (0%)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">Sleepiness</span></td>
<td class="Rrule" align="left">2 (1.1%)</td>
<td class="Rrule" align="left">1 (0.5%)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="4151171" conceptname="Numbness of limbs">Numbness</span> and <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">tingling</span></td>
<td class="Rrule" align="left">1 (0.5%)</td>
<td class="Rrule" align="left">2 (1%)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="315078" conceptname="Palpitations">Palpitation</span></td>
<td class="Rrule" align="left">0 (0%)</td>
<td class="Rrule" align="left">2 (1.%)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Ear symptoms (<span class="product-label-link" type="condition" conceptid="380733" conceptname="Otalgia">earache</span>, <span class="product-label-link" type="condition" conceptid="372328" conceptname="Otitis media">otitis media</span>)</td>
<td class="Rrule" align="left">1 (0.5%)</td>
<td class="Rrule" align="left">2 (1%)</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">Cough</span>, persistent <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">cough</span></td>
<td class="Rrule" align="left">0 (0%)</td>
<td class="Rrule" align="left">2 (1%)</td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-6.1.2"></a><p></p>
<p class="First"><span class="Italics">Adverse reactions observed in less than 1% of patients: </span></p>
<a name="table4"></a><table width="75%">
<caption><span>Table 4: Adverse Reactions in Controlled Trials with an Incidence of Less than 1% but Considered Clinically Relevant in Patients Administered Septocaine®</span></caption>
<col align="left" valign="top" width="50%">
<col align="left" valign="top" width="50%">
<thead><tr class="First Last">
<th class="Lrule Rrule" align="left">Body System</th>
<th class="Rrule" align="left">Reactions</th>
</tr></thead>
<tbody>
<tr class="Botrule First">
<td class="Lrule Rrule" align="left">Body as a Whole</td>
<td class="Rrule" align="left"><span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">Asthenia</span>; <span class="product-label-link" type="condition" conceptid="134736" conceptname="Backache">back pain</span>; <span class="product-label-link" type="condition" conceptid="4316207" conceptname="Injection site pain">injection site pain</span>; <span class="product-label-link" type="condition" conceptid="4235891" conceptname="Burning sensation">burning sensation</span> above injection site; <span class="product-label-link" type="condition" conceptid="4272240" conceptname="Malaise">malaise</span>; <span class="product-label-link" type="condition" conceptid="24134" conceptname="Neck pain">neck pain</span></td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Cardiovascular System</td>
<td class="Rrule" align="left"><span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">Hemorrhage</span>; <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span>; <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">syncope</span>; <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span>; elevated blood pressure</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Digestive System</td>
<td class="Rrule" align="left"><span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">Dyspepsia</span>; <span class="product-label-link" type="condition" conceptid="436147" conceptname="Glossitis">glossitis</span>; <span class="product-label-link" type="condition" conceptid="4311406" conceptname="Bleeding gums">gum hemorrhage</span>; <span class="product-label-link" type="condition" conceptid="4094986" conceptname="Ulcer of mouth">mouth ulceration</span>; <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>; <span class="product-label-link" type="condition" conceptid="138455" conceptname="Stomatitis">stomatitis</span>; <span class="product-label-link" type="condition" conceptid="4217627" conceptname="Edema of the tongue">tongue edemas</span>; <span class="product-label-link" type="condition" conceptid="4122115" conceptname="Tooth disorder">tooth disorder</span>; <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span></td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Hemic and Lymphatic System</td>
<td class="Rrule" align="left"><span class="product-label-link" type="condition" conceptid="4118793" conceptname="Ecchymosis">Ecchymosis</span>; <span class="product-label-link" type="condition" conceptid="315085" conceptname="Lymphadenopathy">lymphadenopathy</span></td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Metabolic and Nutritional System</td>
<td class="Rrule" align="left"><span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">Edema</span>; <span class="product-label-link" type="condition" conceptid="4241197" conceptname="Thirst">thirst</span></td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Musculoskeletal System</td>
<td class="Rrule" align="left"><span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">Arthralgia</span>; <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">myalgia</span>; <span class="product-label-link" type="condition" conceptid="141663" conceptname="Osteomyelitis">osteomyelitis</span></td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Nervous System</td>
<td class="Rrule" align="left"><span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">Dizziness</span>; <span class="product-label-link" type="condition" conceptid="4226991" conceptname="Aptyalism">dry mouth</span>; <span class="product-label-link" type="condition" conceptid="374923" conceptname="Bell's palsy">facial paralysis</span>; <span class="product-label-link" type="condition" conceptid="4031840" conceptname="Hyperesthesia">hyperesthesia</span>; <span class="product-label-link" type="condition" conceptid="4207204" conceptname="Excessive salivation">increased salivation</span>; <span class="product-label-link" type="condition" conceptid="436817" conceptname="Feeling nervous">nervousness</span>; <span class="product-label-link" type="condition" conceptid="197608" conceptname="Peripheral neuritis in pregnancy">neuropathy</span>; <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">paresthesia</span>; <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span>; exacerbation of Kearns-Sayre Syndrome</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Respiratory System</td>
<td class="Rrule" align="left"><span class="product-label-link" type="condition" conceptid="4226263" conceptname="Pharyngitis">Pharyngitis</span>; <span class="product-label-link" type="condition" conceptid="4320791" conceptname="Rhinitis">rhinitis</span>; <span class="product-label-link" type="condition" conceptid="4172302" conceptname="Sinus headache">sinus pain</span>; <span class="product-label-link" type="condition" conceptid="4220211" conceptname="Congestion of nasal sinus">sinus congestion</span></td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Skin and Appendages</td>
<td class="Rrule" align="left"><span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">Pruritus</span>; <span class="product-label-link" type="condition" conceptid="140842" conceptname="Changes in skin texture">skin disorder</span></td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" align="left">Special Senses</td>
<td class="Rrule" align="left"><span class="product-label-link" type="condition" conceptid="380733" conceptname="Otalgia">Ear pain</span>;  <span class="product-label-link" type="condition" conceptid="436235" conceptname="Taste sense altered">taste perversion</span></td>
</tr>
</tbody>
</table>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S6.2"></a><a name="section-6.2"></a><p></p>
<h2>6.2	Postmarketing Experience</h2>
<p class="First">The following adverse reactions have been identified during postapproval use of Septocaine®. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a casual relationship to drug exposure.</p>
<p>Persistent <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">paresthesias</span> of the lips, tongue, and oral tissues have been reported with use of articaine hydrochloride, with slow, incomplete, or no recovery. These postmarketing events have been reported chiefly following nerve blocks in the mandible and have involved the trigeminal nerve and its branches.</p>
<p><span class="product-label-link" type="condition" conceptid="4151171" conceptname="Numbness of limbs">Hypoesthesia</span> has been reported with use of articaine, especially in pediatric age groups, which is usually reversible. Prolonged <span class="product-label-link" type="condition" conceptid="4151171" conceptname="Numbness of limbs">numbness</span> can result in soft tissue injuries such as that of the lips and tongue in these age groups.</p>
<p>Ischemic injury and <span class="product-label-link" type="condition" conceptid="4280654" conceptname="Necrosis">necrosis</span> have been described following use of articaine with epinephrine and have been postulated to be due to vascular spasm of terminal arterial branches.</p>
<p><span class="product-label-link" type="condition" conceptid="440377" conceptname="Paralysis">Paralysis</span> of ocular muscles has been reported, especially after posterior, superior alveolar injections of articaine during dental anesthesia. Symptoms include <span class="product-label-link" type="condition" conceptid="373474" conceptname="Diplopia">diplopia</span>, <span class="product-label-link" type="condition" conceptid="4290615" conceptname="Dilated pupil">mydriasis</span>, <span class="product-label-link" type="condition" conceptid="373194" conceptname="Paralytic ptosis">ptosis</span>, and difficulty in abduction of the affected eye. These symptoms have been described as developing immediately after injection of the anesthetic solution and persisting one minute to several hours, with generally complete recovery.</p>
</div>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="S7"></a><a name="section-7"></a><p></p>
<h1>7	DRUG INTERACTIONS</h1>
<p class="First">The administration of local anesthetic solutions containing epinephrine to patients receiving monoamine oxidase inhibitors, nonselective beta-adrenergic antagonists, or tricyclic antidepressants may produce severe, prolonged <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>. Phenothiazines and butyrophenones may reduce or reverse the pressor effect of epinephrine. Concurrent use of these agents should be avoided; however, in situations when concurrent therapy is necessary, careful patient monitoring is essential <span class="Italics">[see <a href="#S5.2">Warnings and Precautions (5.2)</a>].</span></p>
</div>
<div class="Section" data-sectionCode="43684-0">
<a name="S8"></a><a name="section-8"></a><p></p>
<h1>8	USE IN SPECIFIC POPULATIONS</h1>
<div class="Section" data-sectionCode="42228-7">
<a name="S8.1"></a><a name="section-8.1"></a><p></p>
<h2>8.1	Pregnancy</h2>
<div class="Section" data-sectionCode="34077-8">
<a name="section-8.1.1"></a><p></p>
<p class="First">Teratogenic Effects - Pregnancy Category C.</p>
<p>There are no adequate and well-controlled studies in pregnant women with Septocaine®. Articaine hydrochloride and epinephrine (1:100,000) has been shown to increase <span class="product-label-link" type="condition" conceptid="4079844" conceptname="Fetal death">fetal deaths</span> and skeletal variations in rabbits when given in doses approximately 4 times the maximum recommended human dose (MRHD). Septocaine® should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.</p>
<p>In embryo-fetal toxicity studies in rabbits, 80 mg/kg, subcutaneously (approximately 4 times the MRHD based on body surface area) caused <span class="product-label-link" type="condition" conceptid="4079844" conceptname="Fetal death">fetal death</span> and increased fetal skeletal variations, but these effects may be attributable to severe maternal toxicity, including <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span>, observed at this dose. In contrast, no embryo-fetal toxicities were observed when articaine and epinephrine (1:100,000) was administered subcutaneously throughout organogenesis at doses up to 40 mg/kg in rabbits and 80 mg/kg in rats (approximately 2 times the MRHD based on body surface area).</p>
<p>In pre- and postnatal developmental studies subcutaneous administration of articaine hydrochloride to pregnant rats throughout gestation and lactation, at a dose of 80 mg/kg (approximately 2 times the MRHD based on body surface area) increased the number of <span class="product-label-link" type="condition" conceptid="443213" conceptname="Stillbirth">stillbirths</span> and adversely affected passive avoidance, a measure of learning, in pups. This dose also produced severe maternal toxicity in some animals. A dose of 40 mg/kg (approximately equal to the MRHD on a mg/m<span class="Sup">2</span> basis) did not produce these effects. A similar study using articaine and epinephrine (1:100,000) rather than articaine hydrochloride alone produced maternal toxicity, but no effects on offspring.</p>
</div>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="S8.3"></a><a name="section-8.2"></a><p></p>
<h2>8.3	Nursing Mothers</h2>
<p class="First">It is not known whether Septocaine® is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when Septocaine® is administered to a nursing woman. When using Septocaine®, nursing mothers may choose to pump and discard breast milk for approximately 4 hours (based on plasma half life) following an injection of Septocaine® (to minimize infant ingestion) and then resume breastfeeding.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="S8.4"></a><a name="section-8.3"></a><p></p>
<h2>8.4	Pediatric Use</h2>
<p class="First">Safety and effectiveness of Septocaine® in pediatric patients below the age of 4 years have not been established. Safety of doses greater than 7 mg/kg (0.175 mL/kg) in pediatric patients has not been established. Safety and effectiveness was established in clinical trials with 61 pediatric patients between the ages of 4 and 16 years administered articaine hydrochloride 4% and epinephrine 1:100,000 injections. Fifty-one of these patients received doses from 0.76 mg/kg to 5.65 mg/kg (0.9 to 5.1 mL) for simple dental procedures and 10 patients received doses between 0.37 mg/kg and 7.48 mg/kg (0.7 to 3.9 mL) for complex dental procedures. Approximately 13% of these pediatric patients required additional injections of anesthetic for complete anesthesia. Dosages in pediatric patients should be reduced, commensurate with age, body weight, and physical condition <span class="Italics">[see <a href="#S2.2">Dosage and Administration (2.2)</a>].</span></p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="S8.5"></a><a name="section-8.4"></a><p></p>
<h2>8.5	Geriatric Use</h2>
<p class="First">In clinical trials, 54 patients between the ages of 65 and 75 years, and 11 patients 75 years and over received Septocaine® containing epinephrine 1:100,000. Among all patients between 65 and 75 years, doses from 0.43 mg/kg to 4.76 mg/kg (0.9 to 11.9 mL) were administered to 35 patients for simple procedures and doses from 1.05 mg/kg to 4.27 mg/kg (1.3 to 6.8 mL) were administered to 19 patients for complex procedures. Among the 11 patients ≥ 75 years old, doses from 0.78 mg/kg to 4.76 mg/kg (1.3 to 11.9 mL) were administered to 7 patients for simple procedures and doses of 1.12 mg/kg to 2.17 mg/kg (1.3 to 5.1 mL) were administered to 4 patients for complex procedures.</p>
<p>Approximately 6% of patients between the ages of 65 and 75 years and none of the 11 patients 75 years of age or older required additional injections of anesthetic for complete anesthesia compared with 11% of patients between 17 and 65 years old who required additional injections.</p>
<p>No overall differences in safety or effectiveness were observed between elderly subjects and younger subjects, and other reported clinical experience has not identified differences in responses between the elderly and younger patients, but greater sensitivity of some older individuals cannot be ruled out.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S8.6"></a><a name="section-8.5"></a><p></p>
<h2>8.6	Renal/<span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">Hepatic Insufficiency</span></h2>
<p class="First">No studies have been performed with articaine hydrochloride 4% and epinephrine 1:200,000 injection or articaine hydrochloride  4% and epinephrine 1:100,000 injection in patients with renal or hepatic dysfunction <span class="Italics">[see <a href="#S5.2">Warnings and Precautions (5.2)</a>].</span></p>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="S10"></a><a name="section-9"></a><p></p>
<h1>10	OVERDOSAGE</h1>
<p class="First">Acute emergencies from local anesthetics are generally related to high plasma levels encountered during therapeutic use of local anesthetics or to unintended subarachnoid injection of local anesthetic solution <span class="Italics">[see <a href="#S5.1">Warnings and Precautions (5.1</a>, <a href="#S5.2">5.2)</a>].</span></p>
<p>The first consideration is prevention, best accomplished by careful and constant monitoring of cardiovascular and respiratory vital signs and the patient's state of consciousness after each local anesthetic injection. At the first sign of change, oxygen should be administered.</p>
<p>The first step in the management of <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsions</span>, as well as hypo-ventilation, consists of immediate attention to the maintenance of a patent airway and assisted or controlled ventilation as needed. The adequacy of the circulation should be assessed. Should <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsions</span> persist despite adequate respiratory support, treatment with appropriate anticonvulsant therapy is indicated. The practitioner should be familiar with the use of anticonvulsant drugs, prior to the use of local anesthetics. Supportive treatment of circulatory <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> may require administration of intravenous fluids and, when appropriate, a vasopressor.</p>
<p> If not treated immediately, both <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsions</span> and cardiovascular <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> can result in <span class="product-label-link" type="condition" conceptid="4306572" conceptname="Hypoxia">hypoxia</span>, <span class="product-label-link" type="condition" conceptid="435517" conceptname="Acidosis">acidosis</span>, <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span>, <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">arrhythmias</span>, and/or <span class="product-label-link" type="condition" conceptid="321042" conceptname="Cardiac arrest">cardiac arrest</span>. If <span class="product-label-link" type="condition" conceptid="321042" conceptname="Cardiac arrest">cardiac arrest</span> should occur, standard cardiopulmonary resuscitative measures should be instituted.</p>
<p> For additional information about <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> treatment, call a poison control center (<span class="Bold">1-800-222-1222</span>).</p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="S11"></a><a name="section-10"></a><p></p>
<h1>11	DESCRIPTION</h1>
<p class="First">Septocaine® injection is a sterile, aqueous solution that contains articaine HCl 4% (40 mg/mL) and epinephrine bitartrate in an epinephrine 1:200,000 or epinephrine 1:100,000 strength. Articaine HCl is an amino amide local anesthetic, chemically designated as 4-methyl-3-[2-(propylamino)-propionamido]-2-thiophene-carboxylic acid, methyl ester hydrochloride and is a racemic mixture. Articaine HCl has a molecular weight of 320.84 and the following structural formula:</p>
<div class="Figure"><img alt="Chemical Structure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=0eba0bd2-ccb6-4f7e-8d0c-e4b4e6cdce03&amp;name=septocaine-01.jpg"></div>
<p>Articaine HCl has a partition coefficient in n-octanol/Soerensen buffer (pH 7.35) of 17 and a pKa of 7.8.</p>
<p>Epinephrine bitartrate, (-)-1-(3,4-Dihydroxyphenyl)-2-methylamino-ethanol (+) tartrate (1:1) salt, is a vasoconstrictor that is added to articaine HCl in a concentration of 1:200,000 or 1:100,000 (expressed as free base). It has a molecular weight of 333.3 and the following structural formula:</p>
<div class="Figure"><img alt="Chemical Structure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=0eba0bd2-ccb6-4f7e-8d0c-e4b4e6cdce03&amp;name=septocaine-02.jpg"></div>
<p>Septocaine® contains articaine HCl (40 mg/mL), epinephrine (1:200,000 or 1:100,000) (as epinephrine bitartrate), sodium chloride (1.6 mg/mL), and sodium metabisulfite (0.5 mg/mL). The product is formulated with a 15% overage of epinephrine. The pH is adjusted with sodium hydroxide.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="S12"></a><a name="section-11"></a><p></p>
<h1>12   CLINICAL PHARMACOLOGY</h1>
<div class="Section" data-sectionCode="43679-0">
<a name="S12.1"></a><a name="section-11.1"></a><p></p>
<h2>12.1	Mechanism of Action</h2>
<p class="First">Articaine HCl is an amide local anesthetic. Local anesthetics block the generation and conduction of nerve impulses, presumably by increasing the threshold for electrical excitation in the nerve, by slowing the propagation of the nerve impulse, and by reducing the rate of rise of the action potential. In general, the progression of anesthesia is related to the diameter, myelination, and conduction velocity of the affected nerve fibers. Epinephrine is a vasoconstrictor added to articaine HCl to slow absorption into the general circulation and thus prolong maintenance of an active tissue concentration.</p>
</div>
<div class="Section" data-sectionCode="43681-6">
<a name="S12.2"></a><a name="section-11.2"></a><p></p>
<h2>12.2	Pharmacodynamics</h2>
<p class="First">Clinically, the order of loss of nerve function is as follows: (1) <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>; (2) temperature; (3) touch; (4) proprioception; and (5) skeletal muscle tone.</p>
<p>The onset of anesthesia has been shown to be within 1 to 9 minutes of injection of Septocaine®. Complete anesthesia lasts approximately 1 hour for infiltrations and up to approximately 2 hours for nerve block.</p>
<p>Administration of Septocaine® results in a 3- to 5-fold increase in plasma epinephrine concentrations compared to baseline; however, in healthy adults it does not appear to be associated with marked increases in blood pressure or heart rate, except in the case of accidental intravascular injection <span class="Italics">[see <a href="#S5.1">Warnings and Precautions (5.1)</a>].</span></p>
</div>
<div class="Section" data-sectionCode="43682-4">
<a name="S12.3"></a><a name="section-11.3"></a><p></p>
<h2>12.3	Pharmacokinetics</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.3.1"></a><p></p>
<p class="First"><span class="Bold">Absorption:  </span>Following dental injection by the submucosal route of an articaine solution containing epinephrine 1:200,000, articaine reaches peak blood concentration about 25 minutes after a single dose injection and 48 minutes after three doses. Peak plasma levels of articaine achieved after 68 and 204 mg doses are 385 and 900 ng/mL, respectively. Following intraoral administration of a near maximum dose of 476 mg, articaine reaches peak blood concentrations of 2037 and 2145 ng/mL for articaine solution containing epinephrine 1:100,000 and 1:200,000, respectively, approximately 22 minutes post-dose.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.3.2"></a><p></p>
<p class="First"><span class="Bold">Distribution:</span>  Approximately 60 to 80% of articaine HCl is bound to human serum albumin and γ-globulins at 37°C <span class="Italics">in vitro</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.3.3"></a><p></p>
<p class="First"><span class="Bold">Metabolism:</span>  Articaine HCl is metabolized by plasma carboxyesterase to its primary metabolite, articainic acid, which is inactive. <span class="Italics">In vitro</span> studies show that the human liver microsome P450 isoenzyme system metabolizes approximately 5% to 10% of available articaine with nearly quantitative conversion to articainic acid.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.3.4"></a><p></p>
<p class="First"><span class="Bold">Excretion:</span>  At the dose of 476 mg of articaine, the elimination half-life was 43.8 minutes and 44.4 minutes for articaine solution containing  epinephrine 1:100,000 and 1:200,000, respectively. Articaine is excreted primarily through urine with 53-57% of the administered dose eliminated in the first 24 hours following submucosal administration. Articainic acid is the primary metabolite in urine. A minor metabolite, articainic acid glucuronide, is also excreted in urine. Articaine constitutes only 2% of the total dose excreted in urine.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.3.5"></a><p></p>
<p class="First"><span class="Bold">Special Populations<span class="Italics">:  </span></span>No studies have been performed to evaluate the pharmacokinetics of Septocaine® injection in pediatric subjects. There is insufficient information to determine whether the pharmacokinetics of Septocaine® injection differs by race.</p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="43680-8">
<a name="S13"></a><a name="section-12"></a><p></p>
<h1>13   NONCLINICAL TOXICOLOGY</h1>
<div class="Section" data-sectionCode="34083-6">
<a name="S13.1"></a><a name="section-12.1"></a><p></p>
<h2>13.1	Carcinogenesis, Mutagenesis, Impairment of Fertility</h2>
<p class="First">Studies to evaluate the carcinogenic potential of articaine HCl in animals have not been conducted. Five standard mutagenicity tests, including three <span class="Italics">in vitro</span> tests (the nonmammalian Ames test, the mammalian Chinese hamster ovary chromosomal aberration test, and a mammalian gene mutation test with articaine HCl) and two <span class="Italics">in vivo</span> mouse micronucleus tests (one with articaine and epinephrine 1:100,000 and one with articaine HCl alone) showed no mutagenic effects.</p>
<p>No effects on male or female fertility were observed in rats for articaine and epinephrine 1:100,000 administered subcutaneously in doses up to 80 mg/kg/day (approximately 2 times the MRHD based on body surface area).</p>
</div>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="S14"></a><a name="section-13"></a><p></p>
<h1>14   CLINICAL STUDIES</h1>
<p class="First">Three randomized, double-blind, active-controlled studies were designed to evaluate effectiveness of Septocaine® containing epinephrine 1:100,000 as a dental anesthetic. Patients ranging in age from 4 years to over 65 years old underwent simple dental procedures such as single uncomplicated extractions, routine operative procedures, single apical resections, and single crown procedures, or complex dental procedures such as multiple extractions, multiple crowns and/or bridge procedures, multiple apical resections, alveolectomies, muco-gingival operations, and other surgical procedures on the bone. Septocaine® containing epinephrine 1:100,000 was administered as submucosal infiltration and/or nerve block. Efficacy was measured immediately following the procedure by having the patient and investigator rate the patient's <span class="product-label-link" type="condition" conceptid="439502" conceptname="Postoperative pain">procedural pain</span> using a 10 cm visual analog scale (VAS), in which a score of zero represented no <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> and a score of 10 represented the worst <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> imaginable. Mean patient and investigator VAS <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> scores were 0.3-0.4 cm for simple procedures and 0.5-0.6 cm for complex procedures.</p>
<p>Four randomized, double-blind, active-controlled studies were performed comparing Septocaine® containing epinephrine 1:100,000 versus Septocaine® containing epinephrine 1:200,000. The first two studies used electric pulp testers (EPT) to evaluate the success rate (maximum EPT value within 10 minutes), onset, and duration of Septocaine® containing epinephrine 1:100,000 versus Septocaine® containing epinephrine 1:200,000 and articaine solution without epinephrine in healthy adults between 18 and 65 years old. Results indicated that the anesthetic characteristics of the 1:100,000 and 1:200,000 formulations are not significantly different.</p>
<p>A third study compared the difference in visualization of the surgical field after administration of Septocaine® containing epinephrine 1:100,000 versus Septocaine® containing epinephrine 1:200,000 during bilateral maxillary periodontal surgeries in patients ranging from 21 to 65 years old.  Septocaine® containing epinephrine 1:100,000 provided better visualization of the surgical field and less blood loss during the procedures. In a fourth study, designed to assess and compare cardiovascular safety, when the maximum dose of each formulation was administered, no clinically relevant differences in blood pressure or heart rate between formulations were observed.</p>
</div>
<div class="Section" data-sectionCode="34093-5">
<a name="S15"></a><a name="section-14"></a><p></p>
<h1>15	REFERENCES</h1>
<p class="First">Kaplan, EL, editor. Cardiovascular disease in dental practice. Dallas; American Heart Association; 1986.</p>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="S16"></a><a name="section-15"></a><p></p>
<h1>16	HOW SUPPLIED/STORAGE AND HANDLING</h1>
<p class="First">Septocaine® (articaine HCl and epinephrine) Injection is available in 1.7 mL single use glass cartridges, packaged in boxes of 50 cartridges in the following two strengths:</p>
<ul>
<li> Septocaine® containing articaine HCl 4% (40 mg/mL) and epinephrine 1:200,000 (as epinephrine bitartrate 0.009 mg/mL) (NDC 0362-9048-02)</li>
<li> Septocaine® containing articaine HCl 4% (40 mg/mL) and epinephrine 1:100,000 (as epinephrine bitartrate 0.018 mg/mL) (NDC 0362-9049-02)</li>
</ul>
<div class="Section" data-sectionCode="44425-7">
<a name="section-15.1"></a><p></p>
<p class="First"><span class="Bold Italics">Storage and Handling</span></p>
<p>Store at controlled room temperature  25°C (77°F) with brief excursions permitted between 15° and 30°C (59°F-86°F) [see USP Controlled Room Temperature]. Protect from light. Do Not Freeze.</p>
<p>  For chemical disinfection of the carpule, either isopropyl alcohol (91%) or ethyl alcohol (70%) is recommended. Many commercially available brands of isopropyl (rubbing) alcohol, as well as solutions of ethyl alcohol not of U.S.P. grade, contain denaturants that are injurious to rubber and therefore are not to be used.</p>
<p>  Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit.</p>
</div>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="S17"></a><a name="section-16"></a><p></p>
<h1>17	PATIENT COUNSELING INFORMATION</h1>
<p class="First"><span class="Bold"><span class="Italics"><span class="product-label-link" type="condition" conceptid="4141128" conceptname="Absence of sensation">Loss of Sensation</span> and Muscle Function</span>:</span></p>
<ul>
<li> Inform patients in advance of the possibility of temporary <span class="product-label-link" type="condition" conceptid="4141128" conceptname="Absence of sensation">loss of sensation</span> and muscle function following infiltration and nerve block injections [<span class="Italics">see <a href="#S6.2">Adverse Reactions (6.2)</a></span>].</li>
<li> Instruct patients not to eat or drink until normal sensation returns.</li>
</ul>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-17"></a><p></p>
<p class="First">Manufactured for SEPTODONT<br>Louisville, CO 80027<br>by Novocol Pharmaceutical of Canada Inc.<br>Cambridge, Ontario, Canada N1R 6X3<br>Item # 2552-2</p>
<br><br>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-18"></a><p></p>
<p class="First"><span class="Bold">PRINCIPAL DISPLAY PANEL - 1.7 mL Cartridge Carton</span></p>
<p>FOR INFILTRATION AND NERVE BLOCK ANESTHESIA.<br>NDC 0362-9049-02</p>
<p><span class="Bold Italics">Septocaine<span class="Sup">®</span> (articaine HCl and epinephrine) Injection</span></p>
<p><span class="Bold Italics">Articaine hydrochloride 4% and epinephrine 1:100,000</span></p>
<p>Intraoral Submucosal Injection</p>
<p>Contains sodium metabisulfite.<br>See warnings section of insert for details.</p>
<p>50 cartridges: 1.7 mL each</p>
<p><span class="Bold">septodont</span></p>
<p><span class="Bold">Made in Canada by<br>Novocol Pharmaceutical of Canada, Inc.</span></p>
<div class="Figure"><img alt="PRINCIPAL DISPLAY PANEL - 1.7 mL Cartridge Carton" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=0eba0bd2-ccb6-4f7e-8d0c-e4b4e6cdce03&amp;name=septocaine-03.jpg"></div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-19"></a><p></p>
<p class="First"><span class="Bold">PRINCIPAL DISPLAY PANEL - 1.7 mL Cartridge Carton</span></p>
<p>FOR INFILTRATION AND NERVE BLOCK ANESTHESIA.<br>NDC 0362-9048-02</p>
<p><span class="Bold Italics">Septocaine<span class="Sup">®</span> (articaine HCl and epinephrine) Injection</span></p>
<p><span class="Bold Italics">Articaine hydrochloride 4% and epinephrine 1:200,000</span></p>
<p>Intraoral Submucosal Injection</p>
<p>Contains sodium metabisulfite.<br>See warnings section of insert for details.</p>
<p>50 cartridges: 1.7 mL each</p>
<p><span class="Bold">septodont</span></p>
<p><span class="Bold">Made in Canada by<br>Novocol Pharmaceutical of Canada, Inc.</span></p>
<div class="Figure"><img alt="PRINCIPAL DISPLAY PANEL - 1.7 mL Cartridge Carton" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=0eba0bd2-ccb6-4f7e-8d0c-e4b4e6cdce03&amp;name=septocaine-04.jpg"></div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>SEPTOCAINE AND EPINEPHRINE 		
					</strong><br><span class="contentTableReg">articaine hydrochloride and epinephrine bitartrate injection, solution</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0362-9049</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">SUBCUTANEOUS</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>Articaine Hydrochloride</strong> (Articaine) </td>
<td class="formItem">Articaine Hydrochloride</td>
<td class="formItem">40 mg  in 1 mL</td>
</tr>
<tr class="formTableRow">
<td class="formItem">
<strong>Epinephrine Bitartrate</strong> (Epinephrine) </td>
<td class="formItem">Epinephrine Bitartrate</td>
<td class="formItem">0.01 mg  in 1 mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>Sodium chloride</strong></td>
<td class="formItem">1.6 mg  in 1 mL</td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>Sodium metabisulfite</strong></td>
<td class="formItem">0.5 mg  in 1 mL</td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>Water</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>Sodium hydroxide</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0362-9049-02</td>
<td class="formItem">50  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">1.7 mL in 1 CARTRIDGE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA020971</td>
<td class="formItem">01/12/2011</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>SEPTOCAINE AND EPINEPHRINE 		
					</strong><br><span class="contentTableReg">articaine hydrochloride and epinephrine bitartrate injection, solution</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0362-9048</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">SUBCUTANEOUS</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>Articaine Hydrochloride</strong> (Articaine) </td>
<td class="formItem">Articaine Hydrochloride</td>
<td class="formItem">40 mg  in 1 mL</td>
</tr>
<tr class="formTableRow">
<td class="formItem">
<strong>Epinephrine Bitartrate</strong> (Epinephrine) </td>
<td class="formItem">Epinephrine Bitartrate</td>
<td class="formItem">0.005 mg  in 1 mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>Sodium chloride</strong></td>
<td class="formItem">1.6 mg  in 1 mL</td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>Sodium metabisulfite</strong></td>
<td class="formItem">0.5 mg  in 1 mL</td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>Water</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>Sodium hydroxide</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0362-9048-02</td>
<td class="formItem">50  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">1.7 mL in 1 CARTRIDGE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA020971</td>
<td class="formItem">01/12/2011</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Septodont Inc.
							(627058738)
						</td></tr></table>
</div>
<p><div class="EffectiveDate">Revised: 2/2011<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>7b2a8174-0405-4caa-962c-0065ca9eacfa</div>
<div>Set id: 0eba0bd2-ccb6-4f7e-8d0c-e4b4e6cdce03</div>
<div>Version: 4</div>
<div>Effective Time: 20110201</div>
</div>
</div> <div class="DistributorName">Septodont Inc.</div></p>
</body></html>
